1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Molecular Diagnostics Cancer Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Pharmacogenomic Diagnosis
1.2.3 Liquid Biopsy
1.2.4 Other
1.3 Market by Application
1.3.1 Global Molecular Diagnostics Cancer Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Respiratory Cancer
1.3.3 Cancer of Digestive System
1.3.4 Cancer of Urinary System
1.3.5 Cancer of Circulatory System
1.3.6 Motor System Cancer
1.3.7 Reproductive System Cancer
1.3.8 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Molecular Diagnostics Cancer Market Perspective (2017-2028)
2.2 Molecular Diagnostics Cancer Growth Trends by Region
2.2.1 Molecular Diagnostics Cancer Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Molecular Diagnostics Cancer Historic Market Size by Region (2017-2022)
2.2.3 Molecular Diagnostics Cancer Forecasted Market Size by Region (2023-2028)
2.3 Molecular Diagnostics Cancer Market Dynamics
2.3.1 Molecular Diagnostics Cancer Industry Trends
2.3.2 Molecular Diagnostics Cancer Market Drivers
2.3.3 Molecular Diagnostics Cancer Market Challenges
2.3.4 Molecular Diagnostics Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Molecular Diagnostics Cancer Players by Revenue
3.1.1 Global Top Molecular Diagnostics Cancer Players by Revenue (2017-2022)
3.1.2 Global Molecular Diagnostics Cancer Revenue Market Share by Players (2017-2022)
3.2 Global Molecular Diagnostics Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Molecular Diagnostics Cancer Revenue
3.4 Global Molecular Diagnostics Cancer Market Concentration Ratio
3.4.1 Global Molecular Diagnostics Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Molecular Diagnostics Cancer Revenue in 2021
3.5 Molecular Diagnostics Cancer Key Players Head office and Area Served
3.6 Key Players Molecular Diagnostics Cancer Product Solution and Service
3.7 Date of Enter into Molecular Diagnostics Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Molecular Diagnostics Cancer Breakdown Data by Type
4.1 Global Molecular Diagnostics Cancer Historic Market Size by Type (2017-2022)
4.2 Global Molecular Diagnostics Cancer Forecasted Market Size by Type (2023-2028)
5 Molecular Diagnostics Cancer Breakdown Data by Application
5.1 Global Molecular Diagnostics Cancer Historic Market Size by Application (2017-2022)
5.2 Global Molecular Diagnostics Cancer Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Molecular Diagnostics Cancer Market Size (2017-2028)
6.2 North America Molecular Diagnostics Cancer Market Size by Country (2017-2022)
6.3 North America Molecular Diagnostics Cancer Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Molecular Diagnostics Cancer Market Size (2017-2028)
7.2 Europe Molecular Diagnostics Cancer Market Size by Country (2017-2022)
7.3 Europe Molecular Diagnostics Cancer Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Molecular Diagnostics Cancer Market Size (2017-2028)
8.2 Asia-Pacific Molecular Diagnostics Cancer Market Size by Country (2017-2022)
8.3 Asia-Pacific Molecular Diagnostics Cancer Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Molecular Diagnostics Cancer Market Size (2017-2028)
9.2 Latin America Molecular Diagnostics Cancer Market Size by Country (2017-2022)
9.3 Latin America Molecular Diagnostics Cancer Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Molecular Diagnostics Cancer Market Size (2017-2028)
10.2 Middle East & Africa Molecular Diagnostics Cancer Market Size by Country (2017-2022)
10.3 Middle East & Africa Molecular Diagnostics Cancer Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Molecular Diagnostics Cancer Introduction
11.1.4 Roche Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.1.5 Roche Recent Development
11.2 Danaher
11.2.1 Danaher Company Detail
11.2.2 Danaher Business Overview
11.2.3 Danaher Molecular Diagnostics Cancer Introduction
11.2.4 Danaher Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.2.5 Danaher Recent Development
11.3 Siemens
11.3.1 Siemens Company Detail
11.3.2 Siemens Business Overview
11.3.3 Siemens Molecular Diagnostics Cancer Introduction
11.3.4 Siemens Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.3.5 Siemens Recent Development
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Detail
11.4.2 Abbott Laboratories Business Overview
11.4.3 Abbott Laboratories Molecular Diagnostics Cancer Introduction
11.4.4 Abbott Laboratories Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.4.5 Abbott Laboratories Recent Development
11.5 ICON Plc
11.5.1 ICON Plc Company Detail
11.5.2 ICON Plc Business Overview
11.5.3 ICON Plc Molecular Diagnostics Cancer Introduction
11.5.4 ICON Plc Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.5.5 ICON Plc Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Molecular Diagnostics Cancer Introduction
11.6.4 AstraZeneca Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.6.5 AstraZeneca Recent Development
11.7 MDxHealth
11.7.1 MDxHealth Company Detail
11.7.2 MDxHealth Business Overview
11.7.3 MDxHealth Molecular Diagnostics Cancer Introduction
11.7.4 MDxHealth Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.7.5 MDxHealth Recent Development
11.8 Invitae
11.8.1 Invitae Company Detail
11.8.2 Invitae Business Overview
11.8.3 Invitae Molecular Diagnostics Cancer Introduction
11.8.4 Invitae Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.8.5 Invitae Recent Development
11.9 PlexBio
11.9.1 PlexBio Company Detail
11.9.2 PlexBio Business Overview
11.9.3 PlexBio Molecular Diagnostics Cancer Introduction
11.9.4 PlexBio Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.9.5 PlexBio Recent Development
11.10 Thermo Fisher Scientific
11.10.1 Thermo Fisher Scientific Company Detail
11.10.2 Thermo Fisher Scientific Business Overview
11.10.3 Thermo Fisher Scientific Molecular Diagnostics Cancer Introduction
11.10.4 Thermo Fisher Scientific Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.10.5 Thermo Fisher Scientific Recent Development
11.11 Guardant Health
11.11.1 Guardant Health Company Detail
11.11.2 Guardant Health Business Overview
11.11.3 Guardant Health Molecular Diagnostics Cancer Introduction
11.11.4 Guardant Health Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.11.5 Guardant Health Recent Development
11.12 Biocartis
11.12.1 Biocartis Company Detail
11.12.2 Biocartis Business Overview
11.12.3 Biocartis Molecular Diagnostics Cancer Introduction
11.12.4 Biocartis Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.12.5 Biocartis Recent Development
11.13 Bio-Techne
11.13.1 Bio-Techne Company Detail
11.13.2 Bio-Techne Business Overview
11.13.3 Bio-Techne Molecular Diagnostics Cancer Introduction
11.13.4 Bio-Techne Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.13.5 Bio-Techne Recent Development
11.14 Merck
11.14.1 Merck Company Detail
11.14.2 Merck Business Overview
11.14.3 Merck Molecular Diagnostics Cancer Introduction
11.14.4 Merck Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.14.5 Merck Recent Development
11.15 Foundation Medicine
11.15.1 Foundation Medicine Company Detail
11.15.2 Foundation Medicine Business Overview
11.15.3 Foundation Medicine Molecular Diagnostics Cancer Introduction
11.15.4 Foundation Medicine Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.15.5 Foundation Medicine Recent Development
11.16 10X Genomics
11.16.1 10X Genomics Company Detail
11.16.2 10X Genomics Business Overview
11.16.3 10X Genomics Molecular Diagnostics Cancer Introduction
11.16.4 10X Genomics Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.16.5 10X Genomics Recent Development
11.17 Biodesix
11.17.1 Biodesix Company Detail
11.17.2 Biodesix Business Overview
11.17.3 Biodesix Molecular Diagnostics Cancer Introduction
11.17.4 Biodesix Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.17.5 Biodesix Recent Development
11.18 CytoTrack
11.18.1 CytoTrack Company Detail
11.18.2 CytoTrack Business Overview
11.18.3 CytoTrack Molecular Diagnostics Cancer Introduction
11.18.4 CytoTrack Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.18.5 CytoTrack Recent Development
11.19 GenomOncology
11.19.1 GenomOncology Company Detail
11.19.2 GenomOncology Business Overview
11.19.3 GenomOncology Molecular Diagnostics Cancer Introduction
11.19.4 GenomOncology Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.19.5 GenomOncology Recent Development
11.20 Luminex
11.20.1 Luminex Company Detail
11.20.2 Luminex Business Overview
11.20.3 Luminex Molecular Diagnostics Cancer Introduction
11.20.4 Luminex Revenue in Molecular Diagnostics Cancer Business (2017-2022)
11.20.5 Luminex Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
